Accentrix is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD), the treatment of visual impairment due to diabetic macular oedema (DME), the treatment of proliferative diabetic retinopathy (PDR), the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO), the treatment of visual impairment due to choroidal neovascularization (CNV).
Accentrix is indicated in preterm infants for: The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.